Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease

Fig. 2

NfL levels in carrier and control plasma. Plasma NfL levels were measured by Quanterix Simoa assay. a For N = 43 participants who have made at least one study visit, samples were taken from the most recent visit at time of analysis. Dots represent singlicate measurements. Dashed lines for “symptomatic reference ranges” represent mean values reported for symptomatic genetic prion disease patients [17, 20] or median values reported for symptomatic sporadic prion disease patients [22, 23]. b For N = 14 participants who had completed three visits, plasma NfL levels were measured by Quanterix Simoa for all three visits to assess longitudinal dynamics. As in Fig. 1b, CSF from the following three timepoints is represented for each participant: initial visit, 2–4-month follow-up visit, and 10–20-month follow-up visit

Back to article page